Month: December 2025

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Written by Customer Service on December 19, 2025. Posted in Public Companies.

FRIENDSWOOD, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 15, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 83 employees covering an aggregate of 139,494 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company’s 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting annually thereafter in three equal installments, subject to the employee’s continued service through...

Cheer Holding Announces Share Consolidation of Class A Ordinary Shares

Written by Customer Service on December 19, 2025. Posted in Public Companies.

Class A Ordinary Shares Will Begin Trading on a Post-Consolidation Adjusted Basis onDecember 23, 2025 BEIJING, Dec. 19, 2025 (GLOBE NEWSWIRE) — Cheer Holding, Inc. (NASDAQ: CHR) (“Cheer Holding,” “we” or the “Company”), a leading provider of next-generation mobile internet infrastructure and platform services, today announced that it intends to effect a share consolidation of its ordinary shares at a ratio of 1 post-split Class A ordinary share for every 50 pre-split ordinary shares (the “Share Consolidation”) so that every fifty (50) shares issued and outstanding will be combined into one (1) share. The Share Consolidation will become effective at 4:05 p.m. (New York time) on December 22, 2025 (the “Effective Time”). The Company’s Class A ordinary shares will continue to be traded on the Nasdaq Capital Market (“Nasdaq”) under...

AS Ekspress Grupp to acquire traffic training platform Liikluslab

Written by Customer Service on December 19, 2025. Posted in Public Companies.

On 19 December 2025, AS Ekspress Grupp entered the contract for the acquisition of 100% of shares in the traffic training platform Liikluslab Baltic OÜ. Liikluslab Baltic OÜ is a platform for traffic education materials (liikluslab.ee) founded in 2019, which has expanded rapidly and offers services to both private individuals and driving schools. Liikluslab Baltic has two subsidiaries: the traffic learning environment Teooria OÜ (teooria.ee) and Liikluslab Tervis OÜ, which deals with health certificates for driving license applicants. The purpose of the acquisition is to grow the digital business and expand into a new business area. Strategically, the acquisition supports Ekspress Grupp’s long-term goal of increasing revenues from digital subscriptions and services and creates an opportunity for international expansion. After the...

Evaxion provides update on MSD collaboration – retains global rights to Gonorrhea vaccine candidate EVX-B2

Written by Customer Service on December 19, 2025. Posted in Public Companies.

MSD declines to exercise option for EVX-B2 development Evaxion is now able to out-license EVX-B2 to another partner Evaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in preclinical studies There is no impact on Evaxion’s cash runway which extends to the second half of 2027COPENHAGEN, Denmark, December 19, 2025 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has been informed that MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) will not exercise its option for Evaxion’s Gonorrhea vaccine candidate EVX-B2. Consequently, Evaxion retains global rights to EVX-B2 and will look for another potential licensing partner. Earlier this year MSD exercised its option on a separate Evaxion vaccine...

AFARAK GROUP SE´S 2026 FINANCIAL REPORTING CALENDAR

Written by Customer Service on December 19, 2025. Posted in Public Companies.

12:00 London, 14:00 Helsinki, 19 December 2025 – Afarak Group SE (“Afarak” or “the Company”) (LSE: AFRK, NASDAQ: AFAGR) AFARAK GROUP SE´S 2026 FINANCIAL REPORTING CALENDAR Stock Exchange Release Afarak Group SE (“Afarak” or the “Company”) will publish its financial results as follows: – Full Year 2025 Results on Friday 27 February 2026 – Annual Report 2025 during the week commencing 23 March 2026 – Report for six months ending 30 June on Friday 14 August 2026 The Company’s Annual General Meeting is scheduled to be held on Tuesday 9 June 2026. A separate notice of General Meeting will be published prior to the meeting in 2026. Production reports for Q1 2026 will be issued by 30 April 2026, and for Q3 2026 will be issued by 30 October 2026. Helsinki, December 19,...

OTC Markets Group Welcomes Roxmore Resources Inc. to OTCQX

Written by Customer Service on December 19, 2025. Posted in Public Companies.

NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Roxmore Resources Inc. (CSE: RM; OTCQX: GARLF), a Canadian resource company, has qualified to trade on the OTCQX® Best Market. Roxmore Resources Inc. upgraded to OTCQX from the OTCID™ Basic Market. Roxmore Resources Inc. begins trading today on OTCQX under the symbol “GARLF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home...

OKYO Pharma to Ring the Opening Bell at Nasdaq

Written by Customer Service on December 19, 2025. Posted in Public Companies.

LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Executive Chairman and Founder, Gabriele Cerrone and the OKYO management team will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York today. The ceremony will be held from 9:15 AM to 9:45 AM ET, and celebrates OKYO’s ongoing advancements in innovative treatments, including its lead candidate urcosimod, a lipid-conjugated chemerin peptide agonist targeting the ChemR23 G-protein-coupled receptor. The company’s novel approach aims to address a significant unmet need in...

Winnebago Industries Reports First Quarter Fiscal 2026 Results

Written by Customer Service on December 19, 2025. Posted in Earnings Releases And Operating Results.

— Quarterly Net Revenues Increase 12.3%, Driven by Growth in Motorhome and Towable RV Segments — — Improved Top-Line Performance and Cost Discipline Deliver Margin Gains and Strengthen Balance Sheet — — Barletta Continues Share Expansion in U.S. Aluminum Pontoon Segment(1) — — Motorized Offerings from Newmar and Grand Design Fuel Share Growth in Class A and Class C(1) — — Company Raises FY 2026 Earnings Guidance Range — EDEN PRAIRIE, Minn., Dec. 19, 2025 (GLOBE NEWSWIRE) — Winnebago Industries, Inc. (NYSE: WGO), a leading outdoor lifestyle product manufacturer, today reported financial results for the Fiscal 2026 first quarter ended November 29, 2025. First Quarter Fiscal 2026 Financial SummaryNet revenues of $702.7 million compared to $625.6 million in the first...

Whitestone REIT Grows Dividend 5.6%

Written by Customer Service on December 19, 2025. Posted in Dividend Reports And Estimates.

Board of Trustees Authorizes $50 Million Share Repurchase Program Company Announces Transition to Quarterly Dividend Payments HOUSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: WSR) (“Whitestone” or the “Company”) today announced that its Board of Trustees has declared a quarterly cash dividend of $0.1425 per share on the Company’s common shares and operating partnership units for the first quarter of 2026. The new dividend represents a 5.6% increase over the previous quarterly dividend amount. Yesterday, the Company’s Board of Trustees authorized a share repurchase program of up to an aggregate purchase price of $50,000,000. Repurchases of common stock under the share repurchase program may be made from time to time in the open market, in privately negotiated purchases, in accelerated share repurchase programs...

Chicago Atlantic Real Estate Finance Declares Common Stock Dividend of $0.47 for the Fourth Quarter of 2025

Written by Customer Service on December 19, 2025. Posted in Dividend Reports And Estimates.

CHICAGO, Dec. 19, 2025 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI), a commercial mortgage real estate investment trust, announced that its board of directors has declared a regular quarterly cash dividend of $0.47 per share for the fourth quarter of 2025. The regular quarterly dividend, which equates to an annualized rate of $1.88 per common share, is payable on January 15, 2026, to shareholders of record as of the close of business on December 31, 2025. About Chicago Atlantic Real Estate Finance, Inc. Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) is a market-leading commercial mortgage REIT utilizing significant real estate, credit and cannabis expertise to originate senior secured loans primarily to state-licensed cannabis operators in limited-license states in the United States. REFI...

Month: December 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals